Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle invasive bladder cancer

Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle... Purpose To explore the immune phenotype of peripheral blood mononuclear cells (PBMC) in patients with high-risk non- muscle invasive bladder cancer (NMIBC). Methods We prospectively collected blood samples from patients with high-risk NMIBC treated at our institution. PBMC were analyzed by flow cytometry to determine the frequency of T cells and NK cells and the expression of immunoregula - tory molecules (Tim-3, TIGIT and PD-1). PBMC from healthy donors (HD) were included for comparison, and associations with response to BCG were investigated. Results A total of 38 patients were included, 19 BCG responders and 19 BCG refractory. Compared to 16 PBMC from HD, the frequency of total NK cells was significantly higher in patients with NMIBC [15.2% (IQR: 11.4, 22.2) vs. 5.72% (IQR: 4.84, 9.79); p = 0.05], whereas the frequency of T cells was not statistically different. Both Tim-3 and TIGIT expressions were significantly higher in NMIBC compared to HD, particularly in NK cells [13.8% (11.0; 22.4) vs. 5.56% (4.20; 10.2) and 34.9% (18.9; 53.5) vs. 1.82% (0.63; 5.16), respectively; p < 0.001]. Overall, the expression of PD-1 in all cell types was low in both NMIBC patients and HD. The immune phenotype was not significantly different before http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png World Journal of Urology Springer Journals

Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle invasive bladder cancer

Download PDF
8 pages

Loading next page...
 
/lp/springer_journal/immune-phenotype-of-peripheral-blood-mononuclear-cells-in-patients-6Meq00Vstl
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Medicine & Public Health; Urology; Nephrology; Oncology
ISSN
0724-4983
eISSN
1433-8726
DOI
10.1007/s00345-018-2359-7
Publisher site
See Article on Publisher Site

Abstract

Purpose To explore the immune phenotype of peripheral blood mononuclear cells (PBMC) in patients with high-risk non- muscle invasive bladder cancer (NMIBC). Methods We prospectively collected blood samples from patients with high-risk NMIBC treated at our institution. PBMC were analyzed by flow cytometry to determine the frequency of T cells and NK cells and the expression of immunoregula - tory molecules (Tim-3, TIGIT and PD-1). PBMC from healthy donors (HD) were included for comparison, and associations with response to BCG were investigated. Results A total of 38 patients were included, 19 BCG responders and 19 BCG refractory. Compared to 16 PBMC from HD, the frequency of total NK cells was significantly higher in patients with NMIBC [15.2% (IQR: 11.4, 22.2) vs. 5.72% (IQR: 4.84, 9.79); p = 0.05], whereas the frequency of T cells was not statistically different. Both Tim-3 and TIGIT expressions were significantly higher in NMIBC compared to HD, particularly in NK cells [13.8% (11.0; 22.4) vs. 5.56% (4.20; 10.2) and 34.9% (18.9; 53.5) vs. 1.82% (0.63; 5.16), respectively; p < 0.001]. Overall, the expression of PD-1 in all cell types was low in both NMIBC patients and HD. The immune phenotype was not significantly different before

Journal

World Journal of Urology – Springer Journals

Published: Jun 2, 2018

References

  • Cancer statistics, 2017
    Siegel, RL; Miller, KD; Jemal, A
  • Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline
    Chang, SS; Bochner, BH; Chou, R; Dreicer, R; Kamat, AM; Lerner, SP
  • EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016
    Babjuk, M; Böhle, A; Burger, M; Capoun, O; Cohen, D; Compérat, EM
  • The health economics of bladder cancer: an updated review of the published literature
    Yeung, C; Dinh, T; Lee, J
  • Breakthrough of the year 2013. Cancer immunotherapy
    Couzin-Frankel, J
  • The mechanism of action of BCG therapy for bladder cancer—a current perspective
    Redelman-Sidi, G; Glickman, MS; Bochner, BH
  • TNM classification of malignant tumours
    Brierley, J; Gospodarowicz, MK; Wittekind, C
  • Pathology and genetics of tumours of the urinary system and male genital organs
    Eble, JN; Sauter, G; Epstein, JI; Sesterhenn, IA
  • The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases
    Coley, WB
  • Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer
    Lamm, DL; Thor, DE; Harris, SC; Reyna, JA; Stogdill, VD; Radwin, HM
  • prognostic role of neutrophil-to-lymphocyte ratio in primary non-muscle-invasive bladder cancer
    D’Andrea, D; Moschini, M; Gust, K; Abufaraj, M; Özsoy, M; Mathieu, R
  • Systemic immunity is required for effective cancer immunotherapy
    Spitzer, MH; Carmi, Y; Reticker-Flynn, NE; Kwek, SS; Madhireddy, D; Martins, MM
  • The blockade of immune checkpoints in cancer immunotherapy
    Pardoll, DM
  • PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
    Francisco, LM; Salinas, VH; Brown, KE; Vanguri, VK; Freeman, GJ; Kuchroo, VK
  • PD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomy
    Pichler, R; Heidegger, I; Fritz, J; Danzl, M; Sprung, S; Zelger, B
  • The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
    Yu, X; Harden, K; Gonzalez, LC; Francesco, M; Chiang, E; Irving, B
  • The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
    Stanietsky, N; Simic, H; Arapovic, J; Toporik, A; Levy, O; Novik, A
  • The immunoreceptor TIGIT regulates antitumor and antiviral CD8+ T cell effector function
    Johnston, RJ; Comps-Agrar, L; Hackney, J; Yu, X; Huseni, M; Yang, Y
  • Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients
    Fourcade, J; Sun, Z; Benallaoua, M; Guillaume, P; Luescher, IF; Sander, C
  • Tim-3 expression represents dysfunctional tumor infiltrating T cells in renal cell carcinoma
    Cai, C; Xu, Y-F; Wu, Z-J; Dong, Q; Li, M-Y; Olson, JC
  • Preoperative Tim-3 expression on peripheral NK cells is correlated with pathologic TNM staging in colorectal cancer
    Wang, Y; Sun, J; Gao, W; Song, B; Shao, Q; Zhao, L
  • Increased PD-1 + and TIM-3 + TILs during cetuximab therapy inversely correlate with response in head and neck cancer patients
    Jie, H-B; Srivastava, RM; Argiris, A; Bauman, JE; Kane, LP; Ferris, RL
  • Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade
    Silva, IP; Gallois, A; Jimenez-Baranda, S; Khan, S; Anderson, AC; Kuchroo, VK
  • Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma
    Xu, L; Huang, Y; Tan, L; Yu, W; Chen, D; Lu, C
  • Predictive biomarkers of bacillus calmette-guérin immunotherapy response in bladder cancer: where are we now?
    Lima, L; Dinis-Ribeiro, M; Longatto-Filho, A; Santos, L
  • Prognostic value of purified protein derivative skin test and granuloma formation in patients treated with intravesical bacillus Calmette-Guerin
    Kelley, DR; Haaff, EO; Becich, M; Lage, J; Bauer, WC; Dresner, SM
  • Systemic immune response after intravesical instillation of bacille Calmette-Guérin (BCG) for superficial bladder cancer
    Taniguchi, K; Koga, S; Nishikido, M; Yamashita, S; Sakuragi, T; Kanetake, H
  • Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer
    Raj, GV; Herr, H; Serio, AM; Donat, SM; Bochner, BH; Vickers, AJ
  • Proliferation of PD-1 + CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients
    Kamphorst, AO; Pillai, RN; Yang, S; Nasti, TH; Akondy, RS; Wieland, A
  • Immunotherapy with checkpoint blockade in the treatment of urothelial carcinoma
    Siefker-Radtke, AO; Apolo, AB; Bivalacqua, TJ; Spiess, PE; Black, PC